![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 39, 27407-27414, September 24, 1999
,
,From the Institut für Pharmakologie und Toxikologie der Albert-Ludwigs-Universität Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg, Germany
| |
ABSTRACT |
|---|
|
|
|---|
Clostridium botulinum exoenzyme C3
inactivates the small GTPase Rho by ADP-ribosylation. We used a C3
fusion toxin (C2IN-C3) with high cell accessibility to study the
kinetics of Rho inactivation by ADP-ribosylation. In primary cultures
of rat astroglial cells and Chinese hamster ovary cells, C2IN-C3
induced the complete ADP-ribosylation of RhoA and concomitantly the
disassembly of stress fibers within 3 h. Removal of C2IN-C3 from
the medium caused the recovery of stress fibers and normal cell
morphology within 4 h. The regeneration was preceded by the
appearance of non-ADP-ribosylated RhoA. Recovery of cell morphology was
blocked by the proteasome inhibitor lactacystin and by the translation
inhibitors cycloheximide and puromycin, indicating that intracellular
degradation of the C3 fusion toxin and the neosynthesis of Rho were
required for reversal of cell morphology. Escherichia coli
cytotoxic necrotizing factor CNF1, which activates Rho by deamidation
of Gln63, caused reconstitution of stress fibers and cell
morphology in C2IN-C3-treated cells within 30-60 min. The effect of
CNF1 was independent of RhoA neosynthesis and occurred in the presence of completely ADP-ribosylated RhoA. The data show three novel findings;
1) the cytopathic effects of ADP-ribosylation of Rho are rapidly
reversed by neosynthesis of Rho, 2) CNF1-induced deamidation activates
ADP-ribosylated Rho, and 3) inhibition of Rho activation but not
inhibition of Rho-effector interaction is a major mechanism underlying
inhibition of cellular functions of Rho by ADP-ribosylation.
The low molecular mass GTPases of the Rho family (Rho, Rac, and
Cdc42) play key roles in the control of the actin cytoskeleton (1). In
several cell lines, activation of RhoA induces formation of stress
fibers and focal adhesions (2), whereas Rac and Cdc42 cause the
formation of lamellipodia and filopodia, respectively (2-4). Moreover,
Rho GTPases act as molecular switches in various signaling processes
(5) including secretion (6), phagocytosis (7), endocytosis (8, 9), cell
cycle progression (10), transcriptional activation (11), and
transformation (12).
Rho proteins are the eukaryotic targets of various bacterial toxins
that inactivate or activate the GTPases by covalent modification (13).
Whereas the large clostridial cytotoxins (e.g.
Clostridium difficile toxins A and B) inactivate Rho GTPases
by glucosylation at Thr35/37 (14, 15), the cytotoxic
necrotizing factor from Escherichia coli (E. coli
CNF1) activates the GTPases by deamidation of
Gln61/63 (16-18). Moreover, RhoA, -B, and -C but not Rac1
and Cdc42 are substrates of exoenzyme C3 from Clostridium
botulinum (19-21) or Clostridium limosum (22), which
inactivates the GTPases by ADP-ribosylation at Asn41 (22).
C3 exoenzyme in particular is widely used as a cell biological tool to
study the functions of Rho (23).
Inasmuch as C3 exoenzyme appears to enter cells via nonspecific
pinocytosis, its cell accessibility is poor (24). Recently, we
constructed a C3 fusion toxin, which enters cells by using the binary
C. botulinum C2 toxin as a carrier (25). The
actin-ADP-ribosylating C2 toxin consists of the ~80-kDa binding
component (C2II) and the 49-kDa enzymatic component (C2I) (26-28).
Both C2 components are separate proteins which assemble at the cell
surface after C2II has bound to an unknown receptor. The C3 fusion
toxin (C2IN-C3) contains the N-terminal domain (amino acid residues 1- 225) of C2I (C2IN), which has no enzyme activity but binds to the C2II component and is sufficient for translocation of C2I into the cytosol.
In contrast to C3 exoenzyme, the C2IN-C3 fusion toxin enters cells
readily and causes the depolymerization of stress fibers at low toxin
concentration within a few hours (25). Thus, C2IN-C3 allows the study
of the kinetics of the cellular intoxication process in more detail.
Here we report that the cytopathic effects of the C2IN-C3 fusion toxin
are rapidly reversed after removal of the toxin. Reversal of the
C3-induced alterations of the cytoskeleton is caused by rapid
degradation of the toxin and by resynthesis of Rho. Moreover, we show
that the Rho-deamidating toxin CNF1 reverses the effects of C2IN-C3
most likely by reactivating ADP-ribosylated Rho. The data provide new
insights into the mechanism of the action of C3 and indicate that
ADP-ribosylated Rho is still able to interact with effectors and to
activate their targets.
Materials and Chemicals--
Cell culture medium was purchased
from Biochrom (Berlin, Germany), fetal calf serum from PAN Systems
(Aidenbach, Germany) and Life Technologies, Inc. (Heidelberg, Germany),
and cell culture materials from Falcon (Heidelberg, Germany). Lab-Tec
chamber slides were from Permanox (Nunc, Germany). The C2II binding
component from the C. botulinum C2 toxin was purified and
activated with trypsin as described (26, 29). The C2IN-C3 fusion toxin
(25) and CNF1 (16) were purified as recombinant
GST1 fusion proteins as
described. The pGEX-LBC construct was kindly donated by Denniz Toksoz,
Harvard Medical School, Boston, MA (30). LBC was purified as a
recombinant GST fusion protein.
2'-(3')-O-(N-Methylanthraniloyl)guanosine 5'-diphosphate (mant-GDP) was prepared as described (31). The pGEX2T
vector (included in the GST Gene Fusion System) and
glutathione-Sepharose 4B were from Amersham Pharmacia Biotech (Uppsala,
Sweden). Anti-RhoA-antibody and horseradish peroxidase-coupled
anti-mouse antibody were from Santa Cruz (Heidelberg, Germany).
Rhodamine-phalloidin, puromycin and cycloheximide were purchased from
Sigma (Deisenhofen, Germany). [32P]NAD (30 Ci/mmol) was
from NEN Life Science Products (Bad Homburg, Germany). Nylon membrane
for RNA blotting, the DIG in vitro transcription kit, and
the DIG DNA labeling and detection kit were from Roche Molecular
Biochemicals (Mannheim, Germany). Lactacystin was from Calbiochem (Bad
Soden, Germany).
Cell Culture--
CHO-K1 cells were cultivated in tissue culture
flasks at 37 °C and 5% CO2 in Ham's F-12/Dulbecco's
modified Eagle's medium (1:1) containing 5% heat-inactivated (30 min,
56 °C) fetal calf serum, 2 mM L-glutamate,
100 units/ml penicillin, and 100 µg/ml streptomycin. Cells were
routinely trypsinized and reseeded twice a week. Primary cultures of
rat astroglial cells were set up as described previously (32, 33). For
cytotoxicity and regeneration assays, subconfluent cells (about
105 to 5 × 105 cells/cm2) in
3-cm plates containing coverslips or cells growing on Lab-Tec chamber
slides were treated for different times with 200 ng/ml activated C2II
together with 100 ng/ml C2IN-C3. CNF1 was used in a final concentration
of 300 ng/ml medium. For regeneration assays cells were treated with
the respective toxin for 3 h; then the cells were washed 5 times
with prewarmed medium, new medium without any toxin was added, and the
cells were incubated at 37 °C.
Actin Staining--
For fluorescence staining of F-actin, cells
were fixed in 4% paraformaldehyde containing 0.1% Triton X-100 for 30 min. Thereafter, cells were briefly washed and incubated for 30 min
with rhodamine-phalloidin (600 ng/ml).
ADP-ribosylation Assay of Rho--
Cells were treated with the
respective toxins as indicated. After incubation they were washed with
cold PBS, harvested in 400 µl of cold lysis buffer (2 mM
MgCl2, 0.1 mM phenylmethylsulfonyl fluoride, 20 µg/ml leupeptin, 80 µg/ml benzamidine in 50 mM HEPES, pH 7.4) and sonicated. Aliquots (100 µg of protein) of the lysate were incubated with [32P]NAD and 50 ng of C2IN-C3 fusion
toxin at 37 °C for 30 min, Laemmli buffer was added, the samples
were heated for 3 min at 95 °C and run on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
[32P]ADP-ribosylated proteins were detected by
autoradiography with a PhosphorImager from Molecular Dynamics (Krefeld, Germany).
SDS-PAGE and Western Blotting--
SDS-PAGE was performed
according to Laemmli (34). For immunoblot analysis, the proteins were
transferred onto a nitrocellulose membrane. The membrane was blocked
for 30 min with 5% nonfat dry milk in PBS containing 0.05% Tween 20 (PBS-T) and the proteins were probed with anti-RhoA antibody (mouse,
1:2000 in PBS-T). After washing with PBS-T, the blot was incubated for
1 h with an anti-mouse antibody coupled to horseradish peroxidase
(1:2000 in PBS-T). The membrane was washed again, and proteins were
visualized using the ECL system according to the manufacturer's instructions.
Extraction and Filter Hybridization of RNA--
Total RNA was
extracted by the guanidine hydrochloride method (35). Seven-µg
aliquots were separated by denaturing gel electrophoresis (1.25%
formaldehyde agarose gels; running buffer was 20 mM MOPS, 8 mM NaAc, and 1 mM EDTA) and electroblotted onto
a nylon membrane. The following nonradioactive DIG filter hybridization
and detection of RhoA mRNA was performed as described previously
(36, 37).
Fluorescence Assay for Nucleotide Exchange--
All measurements
were done on a LS50B spectrofluorometer from Perkin Elmer at 37 °C.
First RhoA was loaded with the fluorescent nucleotide mant-GDP by
incubating 0.5 µM GTPase with 2 µM mant-GDP in buffer C (10 mM triethanolamine, pH 7.5, 150 mM NaCl, 2 mM MgCl2) for 1 h.
Thereafter, the exchange of Rho-bound mant-GDP for GTP was initiated by
adding 100 µM GTP and 0-20 µM LBC. The exchange of Rho-bound fluorescent mant-GDP for GTP was monitored by the
decrease in fluorescence intensity upon the release of mant-GDP from
RhoA. Exciting of the mant-fluorophor was at 357 nm; emission was
measured at 444 nm. The rate constant for the release of mant-GDP was
determined by fitting the experimental curve with a single exponential
decay using SigmaPlot (Jandel Scientific).
C2IN-C3 Fusion Toxin Rapidly Disassembles Stress Fibers in Rat
Astroglial Cells--
In primary cultures of rat astrocytes, C2IN-C3
fusion toxin caused changes in cell shape and destruction of stress
fibers. These effects started 40 min after addition of the toxin and
were maximal after about 2 h (Fig.
1A). By 40-60 min after
addition of C3 fusion toxin to intact cells, radioactive
[32P]ADP-ribosylation of Rho was no longer observed in
the cell lysate, indicating the complete modification of cellular Rho
(Fig. 1B). The ADP-ribosylation of RhoA was confirmed by
anti-RhoA immunoblot analysis (Fig. 1C). Twenty minutes
after addition of the toxin, a fast moving (unmodified Rho) and a
slower moving RhoA band (ADP-ribosylated Rho) were detected by
immunoblotting. After 40 min, only the ADP-ribosylated RhoA was
observed.
Effects of the C2IN-C3 Fusion Toxin Are Reversible--
To test
whether the effects of the fusion toxin were reversible, astroglial
cells were incubated with the toxin for 3 h. Thereafter, the cells
were extensively washed to remove extracellular toxin. Stress fibers
reappeared 6 h after removal of the toxin, and the recovery was
complete after 24 h (Fig.
2A). Reorganization of stress
fibers was accompanied by the reappearance of the polygonal cell
morphology (Fig. 2A). Removal of the toxin rapidly changed the proportion of ADP-ribosylated and non-modified Rho (Fig.
2B). Four hours after removal of the toxin, i.e.
when the cells started to rebuild their stress fibers, a small amount
of Rho was [32P]ADP-ribosylated. Its level increased with
the duration of toxin withdrawal (Fig. 2B). Accordingly,
4 h after removal of the toxin, non-ADP-ribosylated RhoA was
detected by anti-RhoA immunoblotting and 24 h after toxin
withdrawal only non-ADP-ribosylated RhoA was detected (Fig.
2C).
Reversal of the C3 effects was not cell type-specific. In CHO cells or
HeLa cells, the C3 fusion toxin disassembled stress fibers within
3 h. Removal of the toxin resulted in the reorganization of stress
fibers, adhesion to dish matrix, and restoration of cell morphology.
The recovery started 2-3 h after addition of fresh medium (data not
shown). Reversal of the cytopathic effects seemed to be specific for
the fusion toxin. When CHO cells were treated with 10 µg/ml wild-type
C. limosum C3 exoenzyme for 24 h to induce the "C3
specific" morphology, cells did not recover after removal of the
toxin by medium exchange.
Studies on the Duration of Action of the C2IN-C3 Fusion
Toxin--
Because the cytopathic effects disappeared rapidly after
removal of C2IN-C3 from the medium, we studied whether the toxin was
intracellularly degraded by proteases. When CHO cells were treated for
3 h with the fusion toxin and subsequently incubated for 16 h
in fresh medium in the presence of the proteosome inhibitor lactacystin, cells did not regain their original morphology. In lysates
of these cells, Rho was not radioactively labeled by ADP-ribosylation with [32P]NAD and C3 (Fig.
3A, lane
5). As expected, only a slowly migrating RhoA band was
detected by immunoblotting, indicating the presence of Rho
ADP-ribosylated in intact cells (Fig. 3B, lane
5). Thus, lactacystin prolonged the cellular effects of the
C3 fusion toxin.
Studies on the Recovery of RhoA--
First, we tested whether
recovery of non-ADP-ribosylated Rho was due to cleavage of the
ADP-ribose moiety from Rho by a cellular hydrolase activity. CHO cells
were treated with the C3 fusion toxin for 2 h and then incubated
for 1 h in fresh medium without toxin. Cell lysates were prepared
and incubated for 0, 3, and 6 h at 37 °C. Thereafter, Rho
protein was analyzed by immunoblotting (Fig.
4). Even after incubation of the lysates
for 6 h at 37 °C (Fig. 4, lanes 3 and
6), a significant proteolysis of RhoA was not detected.
Furthermore, in lysates of cells that had been treated with C3 fusion
toxin (lanes 4-6), the slowly migrating band of ADP-ribosylated RhoA remained stable, while a rapidly migrating RhoA
band did not appear. Taking these results together, we were not able to
detect hydrolysis of the ADP-ribosylated RhoA in the lysates.
To test whether the reappearance of non-ADP-ribosylated RhoA after
toxin withdrawal was due to newly synthesized protein, we blocked
protein synthesis with cycloheximide or puromycin. Three hours after
addition of the toxin, endogenous Rho was completely ADP-ribosylated
(no [32P]ADP-ribosylation, Fig.
5B, lane
2) and only the slowly moving ADP-ribosylated RhoA band was
detected in the immunoblot (Fig. 5C, lane
2). When cycloheximide or puromycin was present after toxin
withdrawal, regeneration of stress fibers (Fig. 5A) and [32P]ADP-ribosylation of Rho was not observed (Fig.
5B, lanes 5 and 7).
Moreover, the immunoblot did not show unmodified RhoA (Fig. 5C, lanes 5 and 7). All
these data suggested that protein neosynthesis, not hydrolysis of
ADP-ribosylated RhoA, was responsible for the reappearance of
non-ADP-ribosylated RhoA.
Northern blot analysis of total RNA extracts from CHO cells was used to
investigate whether the rapid neosynthesis was initiated by an increase
in RhoA mRNA. Neither addition of the C3 toxin (added for 3 h)
nor its removal had any effect on the amount of RhoA mRNA (Fig.
6). Apparently, neosynthesis of RhoA
protein is due to ongoing protein synthesis.
C3-induced Destruction of the Actin Cytoskeleton Is Prevented and
Rapidly Reversed by CNF1--
Because a small amount of newly
synthesized RhoA protein appeared to induce the complete reassembly of
actin filaments and reconstitution of the cellular morphology, we
tested whether this process could be enhanced by incubation of
C3-treated cells with the E. coli cytotoxic necrotizing
factor, CNF1, which activates Rho by deamidation (16, 18). Therefore,
actin stress fibers of CHO cells were destroyed by treatment (3 h) with
the C3 fusion toxin (Fig. 7). The cells
were subsequently incubated for 2 h with CNF1 in the presence of
the C3 fusion toxin. Surprisingly, the cells started to form actin
stress fibers as early as 60 min after CNF1 addition. The CNF1-induced
rearrangement of the actin cytoskeleton was accompanied by a total
reconstitution of "normal" cell morphology within about 2 h.
CNF1 completely prevented the C3-induced breakdown of actin filaments
when CNF was added 3 h prior to C2IN-C3 fusion toxin (data not
shown). When both toxins were added together at the same time, a weak
C3-induced disassembly of actin filaments was observed after 60 min.
This effect was completely reversed by CNF1 within another 60 min. The
same rapid recovery of actin stress fibers was observed when NIH 3T3
fibroblasts were exposed to the various toxin combinations (data not
shown).
C3-induced ADP-ribosylation of Rho in the Presence of
CNF1--
Next we analyzed the extent of ADP-ribosylation of Rho after
CNF1 treatment. As shown in Fig. 8, in
C3-treated cells RhoA remained completely ADP-ribosylated even after
treatment of cells with CNF1 for 3 h (lane
4) (note that at this time point all cells exhibited
complete recovery of the actin cytoskeleton). Additionally, when
C2IN-C3 and CNF1 were added together, RhoA was ADP-ribosylated (lane 5). After 3 h, the cells showed no
disassembly of stress fibers or C3-typical cytopathic effects on cell
morphology. Finally, preincubation of cells with CNF1 for 3 h did
not prevent C3-induced ADP-ribosylation. Similar results were obtained
with NIH 3T3 cells (data not shown).
The effects of CNF1 on the C3-induced alteration of cellular morphology
occurred very rapidly, suggesting that the recovery of cell morphology
was not caused by neosynthesis of Rho. However, to exclude that CNF1
accelerated the expression of Rho and to rule out that a very small
amount of neosynthesized RhoA was sufficient for rebuilding of the
actin cytoskeleton, we tested the toxin in combination with inhibitors
of protein synthesis. Therefore, CHO cells were treated for 16 h
with the C3 fusion toxin in the presence of cycloheximide.
Subsequently, the cells were incubated with CNF1 for another 2 h
in the presence of cycloheximide. Thereafter, cells were lysed and Rho
was [32P]ADP-ribosylated by C3. Fig.
9A shows that no radioactive
labeling of Rho was detected in lysates of cells pretreated with C3 or C3 plus CNF1. In contrast, pretreatment of cells with CNF1 did not
inhibit the radiolabeling of Rho. These findings indicated that Rho
from cells treated with fusion toxin and additionally with CNF1 was
completely ADP-ribosylated. The anti-RhoA immunoblot (Fig.
9B) confirmed the ADP-ribosylation of RhoA and showed an additional shift of Rho due to CNF1-induced modification. Taken together, these results demonstrated that, despite the ADP-ribosylation of cellular Rho, CNF1 treatment causes complete and rapid
reorganization of the actin cytoskeleton, even under conditions
excluding the de novo synthesis of Rho.
Effect of ADP-ribosylation on Nucleotide Exchange of RhoA Activated
by the Exchange Factor LBC--
The results described above
(e.g. activation of ADP-ribosylated Rho by CNF1) suggested
that inhibition of Rho function by ADP-ribosylation is not caused by a
blockade of the interaction of the GTPase with its effectors but rather
by inhibition of its activation. To test this hypothesis, we studied
the nucleotide release of ADP-ribosylated Rho previously loaded with
mant-GDP in the presence of the Rho-specific nucleotide exchange factor LBC (30). As shown in Fig.
10A, the release of mant-GDP
of control RhoA was stimulated by GST-LBC by about 13-fold, whereas LBC
stimulated the release of the nucleotide from ADP-ribosylated Rho only
by about 1.5-fold. This dramatic reduction in the activation of GDP release was observed over a broad concentration range of LBC (Fig. 10B).
To study kinetics and functional consequences of Rho
ADP-ribosylation in intact cells, we used the C2IN-C3 fusion toxin that uses the cell delivery system of the binary C. botulinum C2
toxin to enter target cells (25). C2IN-C3 caused rapid disassembly of
stress fibers and major changes in morphology in cultured rat astroglial cells and in CHO cells. The effects started within 40 min
and were maximal about 2 h after toxin addition. As reported for
the effects of the C3 exoenzyme (38, 39), these changes in morphology
were preceded by a complete ADP-ribosylation of Rho. Surprisingly, the
cells recovered within a few hours after removal of the toxin from the
medium. Apparently, this recovery of the normal cell morphology
depended on the occurrence of non-ADP-ribosylated RhoA. Concomitantly
with the start of the rebuilding of stress fibers, a small amount of
non-ADP-ribosylated RhoA was detected. Twenty-four hours after toxin
removal, when reconstitution of the actin cytoskeleton and regeneration
of cellular morphology were complete, only non-ADP-ribosylated Rho was
observed. Subsequently, we tested whether reappearance of
non-ADP-ribosylated Rho result from cleavage of the ADP-ribose moiety
of modified Rho or from de novo synthesis of the GTPase.
Cleavage of arginine-linked ADP-ribose is catalyzed by specific
ADP-ribosylarginine hydrolases (40), but ADP-ribosylasparagine
hydrolase has not been identified so far. Moreover, we were not able to
obtain any evidence for a cleavage of the ADP-ribose moiety attached to
Rho by hydrolase activity. In contrast, the translation inhibitors
cycloheximide and puromycin blocked de novo synthesis of
RhoA and prevented the recovery of cell morphology. This finding
strongly suggested that Rho neosynthesis is crucial for reversal of
cell morphology. Since Northern blot analysis did not show an increase
in RhoA mRNA after treatment with C2IN-C3 or after its removal, the
rapid de novo synthesis of RhoA was not due to enhanced
transcription. Therefore, we conclude that the constitutive
biosynthesis of RhoA is sufficient to restore RhoA functions.
Morphological changes were reversed when neosynthesis had provided at
approximately 10% of the normal cellular content of Rho but when
ADP-ribosylated Rho was still present. Thus, our findings do not
support a dominant negative role of ADP-ribosylated Rho as suggested
from microinjection studies (39). This discrepancy may be explained by
the high protein concentration usually used in such microinjection studies.
In addition to rapid neosynthesis of RhoA, the recovery of normal cell
morphology depended on the intracellular degradation of the toxin.
Since addition of the proteasome inhibitor lactacystin prevented the
recovery of the normal cell morphology, the C2IN-C3 fusion toxin was
probably degraded by the proteosomal pathway (41). Similarly, toxin
degradation by the proteosomal pathway has been recently described for
a fusion protein of anthrax toxin, which is related to C2 toxin (42).
In the presence of lactacystin only ADP-ribosylated Rho was detected,
indicating that the ADP-ribosylating activity persisted in the cytosol
and immediately modified the neosynthesized Rho. The data suggested
that a continuous delivery of the toxin into the cytosol occurs in the
presence of extracellular C2IN-C3. Consequently, the ADP-ribosylation
of RhoA persists as long as the toxin is supplied. In contrast, cells
treated with the C. limosum C3 exoenzyme did not recover
within 24 h after removal of the toxin (data not shown). This
difference in cell recovery may be explained by the different
structures of the toxins and/or by the different modes and extent of
cellular uptake.
In addition, E. coli cytotoxic necrotizing factor CNF1
reversed the morphological changes induced by C2IN-C3. CNF1 catalyzes the deamidation of glutamine at position 63 of Rho (16, 18). This
modification blocks the GTPase activity of Rho and renders Rho
constitutively active. The recovery of the flat cell morphology after
removal of C2IN-C3 occurred much more rapidly in the presence than in
the absence of CNF1. Surprisingly, recovery of the cell morphology and
formation of stress fibers were induced by CNF1 even in the presence of
C2IN-C3. Moreover analysis of Rho from cells treated in parallel with
both toxins (e.g. CNF1 and C2IN-C3) revealed complete
ADP-ribosylation of the GTPase. Thus, CNF1 was able to restore stress
fiber formation despite the complete ADP-ribosylation of Rho. Recently,
it has been described in Hep-2 cells that CNF1 prevented the cytopathic
effects of C3B, a C3 fusion toxin consisting of C3 and the
binding/translocation domain of diphtheria toxin (43). In this report
it was suggested that CNF1 prevents ADP-ribosylation of Rho by C3 (43).
In contrast, our data indicate that ADP-ribosylation and deamidation of
Rho by CNF1 and C3, respectively, occur in parallel, but the functional
consequences induced by CNF1 appear to be dominant. In addition to Rho,
CNF1 was shown to deamidate and to activate Rac and Cdc42 (17). Also
these GTPases are involved in organization of the actin cytoskeleton.
However, there is no evidence that Rac and Cdc42 can substitute for Rho
as regards the formation of stress fibers (2, 3). Therefore, our
findings suggest that CNF1 induced the formation of an activated form
of ADP-ribosylated Rho, which still interacted with cellular targets and was capable of activating effectors necessary for the formation of
stress fibers and focal adhesions.
Moreover, this observation provides new insights into the molecular
mechanism underlying the inactivation of Rho by ADP-ribosylation. It
was shown that ADP-ribosylation has no major effects on nucleotide binding as well as hydrolysis of bound GTP. GAP-stimulated GTPase activity is not affected either (39, 44). Because the ADP-ribosylation at Asn41 occurs near the effector region of Rho, it has
been suggested that the ADP-ribosylation blocks the interaction of Rho
with its effectors (22). However, this hypothesis was not supported by findings that ADP-ribosylated Rho interacts with effectors like protein
kinase N (44) or phosphatidyl-4-phosphate 5-kinase (45). Based on the
observation that ADP-ribosylated Rho binds with even higher affinity to
phosphatidyl-4-phosphate 5-kinase than the native RhoA, it was
speculated that the effector activation step but not the binding is
blocked by ADP-ribosylation (45). Our findings suggested that rather
the activation step of Rho is crucially altered by ADP-ribosylation.
This hypothesis was supported by the in vitro studies with
recombinant ADP-ribosylated RhoA, showing that the stimulation of the
GDP release from Rho by the guanine nucleotide exchange factor LBC was
inhibited after ADP-ribosylation. Because the inactivation mechanism of
ADP-ribosylated Rho by GTP hydrolysis is fully functional, a blocked or
diminished activation of Rho will shift the GTPase to its inactive
state (Fig. 11). Thus, after inhibition
of the GTPase activity of Rho by CNF1, ADP-ribosylated Rho becomes
active because the equilibrium between the inactive and active state is
again shifted to the active state (Fig. 11).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (108K):
[in a new window]
Fig. 1.
Time course of the effects of C2IN-C3/C2II on
astroglial cells in primary culture. A, toxin effects
are shown on cells morphology and the actin cytoskeleton. Cells grown
on Lab-Tec chamber slides were incubated with C2IN-C3 (100 ng/ml) and
C2II (200 ng/ml) in the medium. At the indicated times, cells were
fixed and the actin filaments were stained with rhodamine-phalloidin.
Some flat polygonal cells are visualized by dashed lines. Upper part, phase contrast
pictures; lower part, rhodamine-phalloidin
staining of the actin filaments of the respective cells.
Bar = 50 µm. B, ADP-ribosylation of Rho by
C2IN-C3/C2II treatment of astroglial cells. Cells were treated without
toxin (lane 1) or with C2IN-C3/C2II for 20 min
(lane 2), 40 min (lane 3),
60 min (lane 4), 90 min (lane 5), and 120 min (lane 6),
respectively. After toxin treatment, the cells were lysed and lysate
proteins (100 µg) were subjected to an in vitro
[32P]ADP-ribosylation assay with C3 as described under
"Experimental Procedures." Labeled proteins were detected by
SDS-PAGE and autoradiography. C, anti-RhoA immunoblot
analysis of 100 µg of the same lysates described above.
ADP-ribosylated RhoA is indicated by an asterisk.

View larger version (117K):
[in a new window]
Fig. 2.
Reversal of C3 effects by removal of
C2IN-C3/C2II from the medium. A, destruction of actin
filaments induced by C2IN-C3 is reversible in astroglial cells in
primary culture. Cells growing on Lab-Tec chamber slides were treated
for 2 h with 100 ng/ml C2IN-C3 and 200 ng/ml C2II at 37 °C.
Then the medium was removed, and cells were washed and incubated
without toxin for up to 24 h. Immediately (0 h) or after 3, 6, 12, and 24 h, cells were fixed and stained with rhodamine-phalloidin.
Some flat polygonal cells are visualized by dashed lines. The upper part shows the phase
contrast pictures; lower part shows the staining
of actin filaments of respective cells. Bar = 50 µm.
B and C, analysis of ADP-ribosylation of Rho in
astroglial cells after treatment with C2IN-C3/C2II and subsequent
removal of the toxin from the medium. Cells were treated as described
above. Then the medium was removed, and cells were washed and incubated
without toxin. At the indicated times, the cells were lysed. Aliquots
of the cell lysate protein were analyzed for
[32P]ADP-ribosylation of Rho in the ADP-ribosylation
assay with C3 transferase, SDS-PAGE, and subsequent autoradiography
(B). An anti-RhoA immunoblot of the same lysates is shown in
C. Lane 1, control cells;
lane 2, 1-h incubation with C2IN-C3/C2II;
lane 3, 2-h incubation with C2IN-C3/C2II;
lane 4, 6-h incubation with C2IN-C3/C2II;
lane 5, 24-h incubation with C2IN-C3/C2II;
lane 6, 2-h incubation with C2IN-C3/C2II followed
by a 4-h incubation in fresh medium; lane 7, 2-h
incubation with C2IN-C3/C2II followed by a 10-h incubation in fresh
medium; lane 8, 2-h incubation with C2IN-C3/C2II
followed by a 24-h incubation in fresh medium. ADP-ribosylated RhoA is
indicated by an asterisk; n.d., not done for
immunoblot.

View larger version (35K):
[in a new window]
Fig. 3.
Influence of lactacystin on the regeneration
of CHO cells after C2IN-C3/C2II treatment. Cells were incubated
for 3 h with 100 ng/ml C2IN-C3 and 200 ng/ml C2II at 37 °C.
After removal of the medium and washing, cells were incubated in fresh
medium without toxin for an additional 16 h. For inhibition of
proteolytic degradation, cells were incubated with lactacystin (30 µM) in the medium. Cells were lysed, and aliquots (50 µg of protein) were [32P]ADP-ribosylated by C3
transferase and analyzed by anti-RhoA immunoblot. A,
autoradiography of [32P]ADP-ribosylated Rho.
B, anti-RhoA immunoblot. Lane 1,
control cells; lane 2, 16-h incubation with
lactacystin; lane 3, 3-h incubation with
C2IN-C3/C2II; lane 4, 3-h incubation with
C2IN-C3/C2II followed by a 16-h incubation in fresh medium;
lane 5, 3-h incubation with C2IN-C3/C2II followed
by a 16-h incubation in fresh medium + lactacystin. ADP-ribosylated
RhoA is indicated by an asterisk.

View larger version (27K):
[in a new window]
Fig. 4.
Stability of ADP-ribosylated RhoA in lysates
of CHO cells. CHO cells were treated for 3 h with 100 ng/ml
C2IN-C3 and 200 ng/ml C2II or for control without toxin at 37 °C.
After withdrawal of the medium, cells were washed and incubated in
fresh medium without toxin for 1 h. Cells were scraped off into
100 µl of PBS and sonicated, and lysates were incubated in a 37 °C
water bath. At the indicated times, aliquots (100 µg of protein) were
removed and subjected to SDS-PAGE and subsequent immunoblot analysis
with anti-RhoA antibody. Lane 1, control 0-h
incubated; lane 2, control 3-h incubated;
lane 3, control 6-h incubated; lane 4, C2IN-C3 0-h incubated, lane 5,
C2IN-C3 3-h incubated; lane 6, C2IN-C3 6-h
incubated.

View larger version (99K):
[in a new window]
Fig. 5.
Influence of inhibition of protein
neosynthesis on the regeneration of CHO cells after C2IN-C3/C2II
treatment. Cells were incubated for 3 h with 100 ng/ml C2I
and 200 ng/ml C2II at 37 °C. After removal of the medium and
washing, cells were incubated in fresh medium without toxin for another
6 h. For inhibition of protein biosynthesis, cells were incubated
with cycloheximide (20 µM) or puromycin (20 µM) in the medium. For control, cells without toxin
treatment were grown for 9 h with cycloheximide or puromycin,
respectively. At the indicated times, the cells were lysed or fixed for
F-actin staining. A, rhodamine-phalloidin staining.
a, control cells; b, cells treated for 3 h
with C2IN-C3/C2II; c, cells incubated for 3 h with
C2IN-C3/C2II and subsequently for 6 h in fresh medium;
d, cells incubated for 3 h with C2IN-C3/C2II and
subsequently for 6 h in fresh medium in the presence of
cycloheximide. Bar = 50 µm. B, aliquots of
the cell lysates (50 µg of protein) were
[32P]ADP-ribosylated by C3 and detected by
autoradiography. C, anti-RhoA immunoblot. Lane 1, control cells; lane 2, 3-h
incubation with C2IN-C3/C2II; lane 3, 3-h
incubation with C2IN-C3/C2II followed by a 6-h incubation in fresh
medium; lane 4, control cells incubated for
9 h with cycloheximide; lane 5, 3-h
incubation with C2IN-C3/C2II followed by a 6-h incubation in fresh
medium and cycloheximide; lane 6, control cells
incubated for 9 h with puromycin; lane 7,
3-h incubation with C2IN-C3/C2II followed by a 6-h incubation in fresh
medium and puromycin. ADP-ribosylated RhoA is indicated by an
asterisk.

View larger version (43K):
[in a new window]
Fig. 6.
Northern blot analysis of RhoA mRNA in
cultured CHO cells after C2IN-C3/C2II treatment and subsequent removal
of the toxin. Cells were treated with 100 ng/ml C2IN-C3 and 200 ng/ml C2II. After 3 h, cells were washed and incubated in fresh
medium without toxin for the indicated times. The upper panel shows the 28 and 18 S ribosomal bands stained with
ethidium bromide. The lower panel shows
hybridization signals of RhoA (2.2 + 1.8 kilobases) mRNA.
Lane 1, control cells; lane 2, 3-h incubation with C2IN-C3/C2II; lane 3, 5-h incubation with C2IN-C3/C2II; lane 4, 3-h incubation with C2IN-C3/C2II followed by a incubation
for 3 h in fresh medium; lane 5, 3-h
incubation with C2IN-C3/C2II followed by a incubation for 5 h in
fresh medium.

View larger version (110K):
[in a new window]
Fig. 7.
Disassembly of actin filaments induced by
C2IN-C3 is rapidly reversed in CHO cells by CNF1. Cells were
treated for 3 h with 100 ng/ml C2IN-C3 and 200 ng/ml C2II at
37 °C (b). Then GST-CNF1 (300 ng/ml) was added and the
cells were further incubated. After 30 min (d), 60 min
(e), 90 min (f), and 120 min (g), the
cells were fixed and stained with rhodamine-phalloidin. For controls,
cells without toxin (a) and cells treated for 2 h with
GST-CNF1 (c) were used. Cells were fixed, and actin
filaments of respective cells were stained with rhodamine phalloidin.
Bar = 50 µm.

View larger version (38K):
[in a new window]
Fig. 8.
Influence of CNF1 on ADP-ribosylated
Rho. CHO cells were treated with the indicated combinations of
C2IN-C3 (100 ng/ml)/C2II (200 ng/ml) and GST-CNF1 (300 ng/ml), lysed,
and subjected to [32P]ADP-ribosylation by C3 transferase.
Autoradiogram of [32P]ADP-ribosylation assay:
lane 1, control cells; lane 2, cells incubated for 3 h with C2IN-C3 + C2II;
lane 3, cells incubated for 3 h with CNF1;
lane 4, cells incubated for 3 h with C2IN-C3 + C2II and subsequently for 3 h with CNF1; lane 5, cells incubated for 3 h with with C2IN-C3 + C2II
together with CNF1; lane 6, cells incubated for
3 h with CNF1 and subsequently for 3 h with C2IN-C3 + C2II.

View larger version (35K):
[in a new window]
Fig. 9.
Analysis of ADP-ribosylation of Rho in CHO
cells after treatment with C2IN-C3/C2II and CNF1. Cells were
treated for 16 h with 100 ng/ml C2IN-C3 and 200 ng/ml C2II at
37 °C in the presence of 20 µM cycloheximide. Then
GST-CNF1 (300 ng/ml) was added for another 2 h in the presence of
cycloheximide. The cells were lysed, and aliquots (50 µg protein)
were [32P]ADP-ribosylated by C3 transferase and analyzed
by anti-RhoA immunoblot. A, autoradiography of
[32P]ADP-ribosylated Rho. B, anti-RhoA
immunoblot. Lane 1, control cells;
lane 2, 16-h incubation with C2IN-C3/C2II + 20 µM cycloheximide; lane 3, 2-h
incubation with CNF1 (in the presence of cycloheximide);
lane 4, 6-h incubation with C2IN-C3/C2II followed
by 2-h incubation with CNF1 (in the presence of C2IN-C3/C2II and
cycloheximide). RhoA, which is ADP-ribosylated and deamidated, is
indicated by a double asterisk.

View larger version (24K):
[in a new window]
Fig. 10.
Influence of ADP-ribosylation on nucleotide
release of RhoA stimulated by the nucleotide exchange factor LBC.
A, control RhoA (Con-RhoA, 0.5 µM)
and ADP-ribosylated RhoA (ADPr-RhoA, 0.5 µM)
were preloaded with mant-GDP and incubated at 37 °C. Release of the
bound mant-GDP was started by the addition of 100 µM GTP
in the absence (
) or presence of 1 µM GST-LBC (
).
Nucleotide exchange was monitored by the decrease in the fluorescence
of mant-GDP at 444 nm. Exciting of the mant-fluorophor was at 357 nm.
B, plot of the rate constants for release of mant-GDP of
control RhoA (
) and of ADP-ribosylated RhoA (
) determined at the
indicated concentrations of LBC.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (17K):
[in a new window]
Fig. 11.
Effects of ADP-ribosylation and deamidation
on the GTPase cycle of Rho. 1, inactive GDP-bound Rho
is activated by nucleotide exchange, which is facilitated by guanine
nucleotide exchange factors (GEF). The active GTP-bound
state is terminated by hydrolysis of GTP, a process that is largely
accelerated by GTPase-activating proteins (GAP).
2, ADP-ribosylation of Rho inhibits the activation of Rho,
while the off-reaction (GTP hydrolysis) is not inhibited. Therefore,
the active species of Rho cannot accumulate. 3, CNF1
deamidates and thereby blocks the inactivation of Rho. Although Rho is
ADP-ribosylated, the active species accumulates and interacts with
effectors to induce downstream responses.
| |
ACKNOWLEDGEMENTS |
|---|
We gratefully acknowledge the excellent technical assistance of Ulrike Müller and Brigitte Neufang.
| |
FOOTNOTES |
|---|
* This work was supported by Deutsche Forschungsgemeinschaft Sonderforschungsbereich 388 and 505/B4.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Both authors contributed equally to this work.
§ To whom correspondence may be addressed. Tel.: 49-761-2035301; Fax: 49-761-2035311; E-mail: aktories@uni-freiburg.de.
¶ To whom correspondence may be addressed. Tel.: 49-761-2035327; Fax: 49-761-2035326; E-mail: meyerdk@uni-freiburg.de.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GST, glutathione S-transferase; mant-GDP, 2'-(3')-O-(N-methylanthraniloyl)guanosine 5'-diphosphate; CHO, Chinese hamster ovary; PBS, phosphate-buffered saline; PBS-T, PBS plus Tween 20; PAGE, polyacrylamide gel electrophoresis; LBC, lymphoid blast crisis oncogene; MOPS, 4-morpholinepropanesulfonic acid.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Hall, A.
(1998)
Science
279,
509-514 |
| 2. | Ridley, A. J., and Hall, A. (1992) Cell 70, 389-399[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401-410[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Zeeuwen, P. L. J. M.,
Hendriks, W.,
de Jong, W. W.,
and Schalkwijk, J.
(1997)
J. Biol. Chem.
272,
20471-20478 |
| 6. |
Prepens, U.,
Just, I.,
Von Eichel-Streiber, C.,
and Aktories, K.
(1996)
J. Biol. Chem.
271,
7324-7329 |
| 7. |
Caron, E.,
and Hall, A.
(1998)
Science
282,
1717-1721 |
| 8. | Lamaze, C., Chuang, T. H., Terlecky, L. J., Bokoch, G. M., and Schmid, S. L. (1996) Nature 382, 177-179[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Schmalzing, G.,
Richter, H. P.,
Hansen, A.,
Schwarz, W.,
Just, I.,
and Aktories, K.
(1995)
J. Cell Biol.
130,
1319-1332 |
| 10. |
Olson, M. F.,
Ashworth, A.,
and Hall, A.
(1995)
Science
269,
1270-1272 |
| 11. | Reuner, K. H., Wiederhold, M., Dunker, P., Just, I., Bohle, R. M., Kröger, M., and Katz, N. (1995) Eur. J. Biochem. 230, 32-37[Medline] [Order article via Infotrieve] |
| 12. | Khosravi-Far, R., Solski, P. A., Clark, G. J., Kinch, M. S., and Der, C. J. (1995) Mol. Cell. Biol. 15, 6443-6453[Abstract] |
| 13. | Aktories, K. (1997) Trends Microbiol. 5, 282-288[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Just, I., Selzer, J., Wilm, M., Von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503[CrossRef][Medline] [Order article via Infotrieve] |
| 15. |
Just, I.,
Wilm, M.,
Selzer, J.,
Rex, G.,
Von Eichel-Streiber, C.,
Mann, M.,
and Aktories, K.
(1995)
J. Biol. Chem.
270,
13932-13936 |
| 16. | Schmidt, G., Sehr, P., Wilm, M., Selzer, J., Mann, M., and Aktories, K. (1997) Nature 387, 725-729[CrossRef][Medline] [Order article via Infotrieve] |
| 17. |
Lerm, M.,
Selzer, J.,
Hoffmeyer, A.,
Rapp, U. R.,
Aktories, K.,
and Schmidt, G.
(1998)
Infect. Immun.
67,
496-503 |
| 18. | Flatau, G., Lemichez, E., Gauthier, M., Chardin, P., Paris, S., Fiorentini, C., and Boquet, P. (1997) Nature 387, 729-733[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Braun, U., Habermann, B., Just, I., Aktories, K., and Vandekerckhove, J. (1989) FEBS Lett. 243, 70-76[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Aktories, K., Braun, U., Rösener, S., Just, I., and Hall, A. (1989) Biochem. Biophys. Res. Commun. 158, 209-213[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Chardin, P., Boquet, P., Madaule, P., Popoff, M. R., Rubin, E. J., and Gill, D. M. (1989) EMBO J. 8, 1087-1092[Medline] [Order article via Infotrieve] |
| 22. |
Sekine, A.,
Fujiwara, M.,
and Narumiya, S.
(1989)
J. Biol. Chem.
264,
8602-8605 |
| 23. | Aktories, K., and Just, I. (1995) Methods Enzymol. 256, 184-195[Medline] [Order article via Infotrieve] |
| 24. | Aktories, K., Mohr, C., and Koch, G. (1992) Curr. Top. Microbiol. Immunol. 175, 115-131[Medline] [Order article via Infotrieve] |
| 25. |
Barth, H.,
Hofmann, F.,
Olenik, C.,
Just, I.,
and Aktories, K.
(1998)
Infect. Immun.
66,
1364-1369 |
| 26. |
Ohishi, I.,
Iwasaki, M.,
and Sakaguchi, G.
(1980)
Infect. Immun.
30,
668-673 |
| 27. |
Aktories, K.,
and Wegner, A.
(1989)
J. Cell Biol.
109,
1385-1387 |
| 28. | Aktories, K., Bärmann, M., Ohishi, I., Tsuyama, S., Jakobs, K. H., and Habermann, E. (1986) Nature 322, 390-392[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Ohishi, I.
(1987)
Infect. Immun.
55,
1461-1465 |
| 30. |
Zheng, Y.,
Olson, M. F.,
Hall, A.,
Cerione, R. A.,
and Toksoz, D.
(1995)
J. Biol. Chem.
270,
9031-9034 |
| 31. | Hiratsuka, T. (1983) Biochim. Biophys. Acta 742, 496-508[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Keller, M., Jackisch, R., Seregi, A., and Hertting, G. (1985) Neurochem. Int. 7, 655-665[CrossRef] |
| 33. | Hildebrand, B., Olenik, C., Uhl, A., and Meyer, D. K. (1997) Brain Res. 759, 285-291[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Cheley, S., and Anderson, R. (1984) Anal. Biochem. 137, 15-19[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Olenik, C., Barth, H., Just, I., Aktories, K., and Meyer, D. K. (1997) Mol. Brain Res. 52, 263-269[Medline] [Order article via Infotrieve] |
| 37. |
Höltke, H.-J.,
and Kessler, C.
(1990)
Nucleic Acids Res.
18,
5843-5851 |
| 38. | Wiegers, W., Just, I., Müller, H., Hellwig, A., Traub, P., and Aktories, K. (1991) Eur. J. Cell Biol. 54, 237-245[Medline] [Order article via Infotrieve] |
| 39. |
Paterson, H. F.,
Self, A. J.,
Garrett, M. D.,
Just, I.,
Aktories, K.,
and Hall, A.
(1990)
J. Cell Biol.
111,
1001-1007 |
| 40. |
Takada, T.,
Iida, K.,
and Moss, J.
(1993)
J. Biol. Chem.
268,
17837-17843 |
| 41. |
Fenteany, G.,
and Schreiber, S.
(1998)
J. Biol. Chem.
273,
8545-8548 |
| 42. |
Goletz, T. J.,
Klimpel, K. R.,
Arora, N.,
Leppla, S. H.,
Keith, J. M.,
and Berzofsky, J. A.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
12059-12064 |
| 43. | Fiorentini, C., Donelli, G., Matarrese, P., Fabbri, A., Paradisi, S., and Boquet, P. (1995) Infect. Immun. 63, 3936-3944[Abstract] |
| 44. | Sehr, P., Joseph, G., Genth, H., Just, I., Pick, E., and Aktories, K. (1998) Biochemistry 37, 5296-5304[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Ren, X.-D., Bokoch, G. M., Traynor-Kaplan, A., Jenkins, G. H., Anderson, R. A., and Schwartz, M. A. (1996) Mol. Biol. Cell 7, 435-442[Abstract] |
This article has been cited by other articles:
![]() |
H. Barth, K. Aktories, M. R. Popoff, and B. G. Stiles Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins Microbiol. Mol. Biol. Rev., September 1, 2004; 68(3): 373 - 402. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Essler, S. Linder, B. Schell, K. Hufner, A. Wiedemann, K. Randhahn, J. M. Staddon, and M. Aepfelbacher Cytotoxic Necrotizing Factor 1 of Escherichia coli Stimulates Rho/Rho-Kinase-Dependent Myosin Light-Chain Phosphorylation without Inactivating Myosin Light-Chain Phosphatase in Endothelial Cells Infect. Immun., September 1, 2003; 71(9): 5188 - 5193. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Genth, R. Gerhard, A. Maeda, M. Amano, K. Kaibuchi, K. Aktories, and I. Just Entrapment of Rho ADP-ribosylated by Clostridium botulinum C3 Exoenzyme in the Rho-Guanine Nucleotide Dissociation Inhibitor-1 Complex J. Biol. Chem., August 1, 2003; 278(31): 28523 - 28527. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Hopkins, S. V. Walsh, P. Verkade, P. Boquet, and A. Nusrat Constitutive activation of Rho proteins by CNF-1 influences tight junction structure and epithelial barrier function J. Cell Sci., February 15, 2003; 116(4): 725 - 742. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lerm, M. Pop, G. Fritz, K. Aktories, and G. Schmidt Proteasomal Degradation of Cytotoxic Necrotizing Factor 1-Activated Rac Infect. Immun., August 1, 2002; 70(8): 4053 - 4058. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Carton, D. Trouet, D. Hermans, H. Barth, K. Aktories, G. Droogmans, N. K. Jorgensen, E. K. Hoffmann, B. Nilius, and J. Eggermont RhoA exerts a permissive effect on volume-regulated anion channels in vascular endothelial cells Am J Physiol Cell Physiol, July 1, 2002; 283(1): C115 - C125. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Leemhuis, S. Boutillier, G. Schmidt, and D. K. Meyer The Protein Kinase A Inhibitor H89 Acts on Cell Morphology by Inhibiting Rho Kinase J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1000 - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-P. Nougayrede, M. Boury, C. Tasca, O. Marches, A. Milon, E. Oswald, and J. De Rycke Type III Secretion-Dependent Cell Cycle Block Caused in HeLa Cells by Enteropathogenic Escherichia coli O103 Infect. Immun., November 1, 2001; 69(11): 6785 - 6795. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Gulke, G. Pfeifer, J. Liese, M. Fritz, F. Hofmann, K. Aktories, and H. Barth Characterization of the Enzymatic Component of the ADP-Ribosyltransferase Toxin CDTa from Clostridium difficile Infect. Immun., October 1, 2001; 69(10): 6004 - 6011. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. Budnik and A. K. Mukhopadhyay Lysophosphatidic Acid Antagonizes the Morphoregulatory Effects of the Luteinizing Hormone on Luteal Cells: Possible Role of Small Rho-G-Proteins Biol Reprod, July 1, 2001; 65(1): 180 - 187. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wahl, H. Barth, T. Ciossek, K. Aktories, and B. K. Mueller Ephrin-A5 Induces Collapse of Growth Cones by Activating Rho and Rho Kinase J. Cell Biol., April 17, 2000; 149(2): 263 - 270. [Abstract] [Full Text] [PDF] |